Comparative Pharmacology
Head-to-head clinical analysis: METHYLERGONOVINE MALEATE versus WIGRAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLERGONOVINE MALEATE versus WIGRAINE.
METHYLERGONOVINE MALEATE vs WIGRAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergot alkaloid; partial agonist/antagonist at alpha-adrenergic, serotonin (5-HT2), and dopamine receptors; directly stimulates uterine smooth muscle contractions.
WIGRAINE is a combination product containing ergotamine, a vasoconstrictor that acts as an agonist at serotonin (5-HT1B/1D) and alpha-adrenergic receptors, and caffeine, which enhances ergotamine absorption and provides additional vasoconstriction.
0.2 mg intramuscularly or intravenously once, may repeat as needed every 2-4 hours for a maximum of 5 doses.
For acute migraine: 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack, maximum 10 tablets per week.
None Documented
None Documented
Biphasic: initial (alpha) ~10-30 min; terminal (beta) ~2-3 hours in normal subjects; prolonged to ~6-12 hours in hepatic impairment or pregnancy
Ergotamine: ~2-3 hours (terminal). Clinical context: short half-life necessitates frequent dosing for acute migraine relief.
Renal (approximately 60-80% as metabolites, <1% unchanged); biliary/fecal (minor route, approximately 20-30%)
Primarily hepatic metabolism; renal excretion of metabolites. ~90% urinary, ~10% fecal.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid